American Century Companies Inc. Buys 183,776 Shares of Amdocs Limited $DOX

American Century Companies Inc. grew its stake in shares of Amdocs Limited (NASDAQ:DOX) by 12.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,649,077 shares of the technology company’s stock after purchasing an additional 183,776 shares during the period. American Century Companies Inc. owned approximately 1.46% of Amdocs worth $135,307,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in DOX. LSV Asset Management increased its holdings in shares of Amdocs by 7.6% during the third quarter. LSV Asset Management now owns 3,648,703 shares of the technology company’s stock valued at $299,376,000 after acquiring an additional 257,193 shares in the last quarter. New York State Common Retirement Fund grew its position in Amdocs by 20.3% in the 3rd quarter. New York State Common Retirement Fund now owns 554,401 shares of the technology company’s stock valued at $45,489,000 after purchasing an additional 93,527 shares during the period. Illinois Municipal Retirement Fund increased its stake in Amdocs by 46.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 149,539 shares of the technology company’s stock valued at $12,270,000 after purchasing an additional 47,537 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Amdocs by 13.6% during the second quarter. JPMorgan Chase & Co. now owns 266,124 shares of the technology company’s stock worth $24,281,000 after buying an additional 31,827 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in shares of Amdocs by 11.6% in the third quarter. Alps Advisors Inc. now owns 237,883 shares of the technology company’s stock valued at $19,518,000 after buying an additional 24,771 shares in the last quarter. 92.02% of the stock is currently owned by institutional investors and hedge funds.

Amdocs Price Performance

Shares of NASDAQ DOX opened at $69.80 on Monday. The company has a market capitalization of $7.53 billion, a PE ratio of 13.50, a PEG ratio of 1.23 and a beta of 0.42. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.23. The stock’s 50 day moving average price is $77.63 and its 200-day moving average price is $80.47. Amdocs Limited has a twelve month low of $65.74 and a twelve month high of $95.41.

Amdocs (NASDAQ:DOX) last issued its quarterly earnings results on Tuesday, February 3rd. The technology company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.06. Amdocs had a return on equity of 20.19% and a net margin of 12.47%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period last year, the business posted $1.66 earnings per share. Amdocs’s revenue was up 4.1% on a year-over-year basis. Amdocs has set its Q2 2026 guidance at 1.730-1.790 EPS and its FY 2026 guidance at 7.270-7.550 EPS. On average, equities analysts anticipate that Amdocs Limited will post 6.21 EPS for the current year.

Amdocs Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Tuesday, March 31st will be issued a $0.569 dividend. This is an increase from Amdocs’s previous quarterly dividend of $0.53. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.3%. Amdocs’s payout ratio is presently 40.81%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DOX shares. Stifel Nicolaus decreased their target price on shares of Amdocs from $97.00 to $88.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Wall Street Zen upgraded Amdocs from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Wolfe Research reissued a “peer perform” rating on shares of Amdocs in a research note on Thursday, November 13th. Weiss Ratings restated a “hold (c)” rating on shares of Amdocs in a report on Tuesday, January 27th. Finally, Bank of America decreased their price target on Amdocs from $100.00 to $97.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.33.

More Amdocs News

Here are the key news stories impacting Amdocs this week:

• Positive Sentiment: Amdocs announced a multi‑year strategic collaboration with Amazon Web Services to combine Amdocs’ aOS agentic operating system with AWS AI and cloud capabilities to drive telecom modernization — a material commercial & product endorsement that supports future revenue growth. MWC 2026: Amdocs and AWS Announce Multi-Year Strategic Collaboration to Accelerate AI-Driven Telecom Modernization
• Positive Sentiment: Amdocs announced a collaboration with Microsoft to deliver AI‑accelerated application modernization (Amdocs Agentic Services + Microsoft AI), which can expand enterprise services and upsell opportunities. MWC 2026: Amdocs Collaborates with Microsoft to Bring AI-Accelerated Application Modernization to Enterprises
• Positive Sentiment: Amdocs partnered with Google Cloud to combine Gemini Enterprise CX with Amdocs’ Cognitive Core to create an agentic telco contact center — another strategic cloud/A.I. endorsement that could help win telco transformation deals. MWC 2026: Amdocs Collaborates with Google Cloud to Accelerate AI Adoption and Power the Agentic Telco Contact Center
• Positive Sentiment: Zacks Research raised multiple near‑ and medium‑term EPS forecasts (including FY2026/FY2027/FY2028 upgrades and several quarterly raises), which supports a more constructive earnings outlook and could underpin valuation. See Zacks coverage for context. Amdocs (DOX) is a Top-Ranked Growth Stock: Should You Buy?
• Neutral Sentiment: Published short‑interest notices show zero reported short interest and anomalous “NaN” increases across several February reporting dates — this appears to be a data/reporting issue and implies no visible short‑squeeze pressure at present.
• Negative Sentiment: Zacks trimmed its Q2 2026 EPS estimate from $1.60 to $1.50 in the same round of updates — a modest near‑term earnings downgrade that could temper sentiment around the next quarter.
• Negative Sentiment: Technically, the share price is below both the 50‑day and 200‑day moving averages noted in recent quotes, which can invite short‑term selling/ profit‑taking even amid positive fundamental headlines.

Amdocs Company Profile

Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.

Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.